New radiotherapy treatment for brain cancer offers superior preservation of cognitive function, Mayo researchers say
When it comes to radiation therapy to treat brain cancer, hippocampal-avoidance whole-brain radiotherapy in conjunction with the drug memantine better preserved patients’ cognitive function and demonstrated similar cancer control outcomes, compared to traditional whole-brain radiotherapy with memantine.
“The hippocampus is a part of the brain associated with the limbic system and cognitive functions including memory,” says says Paul Brown, M.D., a radiation oncologist at Mayo Clinic and senior author of the study. “Based on decades of translational studies, we know that even relatively modest doses of radiation to the hippocampi region of the brain contributes to cognitive problems for patients, such as memory loss.” Dr. Brown says hippocampal-avoidance whole-brain radiotherapy was developed to help patients with brain cancer avoid cognitive damage during whole-brain radiation therapy.
Click here to read more.
International Conference on Dual Diagnosis and Disorders
Nov. 14-15, 2018; Melbourne, Austrailia
Microsurgical Approaches to Aneurysms and Skull Base Diseases 2018
Nov. 15-17, 2018; Jacksonville, Fla.
2018 Mayo Clinic Multidisciplinary Spine Care Conference
Nov. 16-17, 2018; Amelia Island, Fla.
Craniofacial Surgery and Transfacial Approaches to the Skull Base
Nov. 30-Dec. 2, 2018; St. Louis
Comprehensive Endoscopic Endonasal Surgery of the Skull Base Course
Dec. 5-8, 2018; Pittsburgh
Be the first to reply using the above form.